NX-1607 / Nurix Therap - LARVOL DELTA

Translational Insights from a First-in-Human Study of NX-1607, an Oral CBL-B Inhibitor, in Advanced Solid Tumors (SITC 2025) - P1 | "These findings suggest that NX-1607 has the potential to modulate the tumor microenvironment and elicit antitumor immune responses in heavily pretreated patients with solid tumors. Exploratory biomarker analyses are ongoing to further evaluate PD and to inform on mechanisms of action and resistance to NX-1607.Trial Registration NCT05107674"

First-in-human • IO biomarker • Metastases • P1 data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Oncology • Prostate Cancer • Solid Tumor • CD8 • CXCL10 • IFNG

Developing PROTACs that degrade the Cbl-b E3-ligase | Poster Board #1750 (ACS-Fall 2026) - "Co-crystal structure of Cbl-b and NX-1607 highlighting the exit vectors under exploration for PROTAC synthesis. (PDB: 8GCY)"

Hematological Malignancies • Lymphoma • Targeted Protein Degradation • CRBN

First-in-class CBL-B inhibitor NX-1607: Phase Ia data in patients with advanced solid tumors (ESMO 2025) - P1 | "In heavily pretreated pts, signals of antitumor activity included objective tumor regression, PSA reductions, and a notable disease control rate. This underscores the utility of CBL-B inhibition as an innovative IO therapy with potential for durable clinical benefit."

Clinical • IO biomarker • Metastases • P1 data • Colorectal Cancer • Genito-urinary Cancer • Hematological Malignancies • Lymphoma • Oncology • Prostate Cancer • Solid Tumor

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including DLBCL (ASH 2023) - P1 | "Clinical trial information: NCT05107674. Study contact: [email protected]"

Clinical • First-in-human • IO biomarker • Metastases • P1 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation

Broader Pipeline Highlights (Nurix Press Release) - "Nurix has completed enrollment of current Phase 1a dose escalation cohorts of NX-1607, an investigational oral CBL-B inhibitor, across multiple solid tumor oncology indications and is reviewing the data to determine next steps....Zelebrudomide is an orally bioavailable degrader of BTK and the cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) designed for the treatment of relapsed or refractory B-cell malignancies. Nurix has completed enrollment in the current dose escalation cohorts of the Phase 1 trial (NCT04830137) and is reviewing the data to determine next steps."

Enrollment closed • Platinum resistant • Trial status • Castration-Resistant Prostate Cancer • Cervical Cancer • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Epithelial Ovarian Cancer • Follicular Lymphoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Malignant Pleural Mesothelioma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Melanoma • Non Small Cell Lung Cancer • Primary Central Nervous System Lymphoma • Richter's Syndrome • Small Lymphocytic Lymphoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Urothelial Cancer • Waldenstrom Macroglobulinemia

Discovery and characterization of CBL-B intramolecular glue inhibitors that increase T cell activation and suppress tumor growth (AACR 2026) - "These studies demonstrate that pharmacological inhibition of CBL-B reproduces the reported mouse knockout phenotype. NX-1607, a first-in-class CBL-B inhibitor, is now in clinical development as a potential cancer immunotherapy.Keywords: Immuno-oncology, CBL-B, molecular glue, T-cell activation, small-molecule inhibitor, high-throughput screening, tumor immunity"

IO biomarker • Oncology • CD33 • CD69 • IFNG • IL2RA • TNFA

CBL-B Program (GlobeNewswire) - "Nurix Therapeutics announces new preclinical data...at AACR 2026.... In preclinical studies, NX-1607 enhanced T cell activation, as evidenced by increased IL-2 and IFN-γ secretion in response to TCR stimulation, and demonstrated single-agent anti-tumor activity across multiple syngeneic tumor models, including colorectal, triple-negative breast cancer, and B cell lymphoma. NX-1607 also synergized with anti-PD-1 therapy to significantly enhance survival across multiple models."

Preclinical • B Cell Lymphoma • Colorectal Cancer • Triple Negative Breast Cancer

NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. (PubMed, J Immunother Cancer) - "These findings were validated in an immunocompetent B-cell lymphoma mouse model, where NX-1607 consistently upregulated PLCγ1 and ERK phosphorylation. Together, this work delineates a PLCγ1-MAPK/ERK axis through which Cbl-b inhibition unleashes T cell activation, providing critical insight for the development of NX-1607 based immunotherapy."

IO biomarker • Journal • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CD69

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) - "As of the 26 July 2025 data cut, 71 patients were evaluable for response, with a disease control rate (DCR) of 49.3%. With respect to duration of response, 7 patients achieved either stable disease (SD) or partial response (PR) for ≥5 months on treatment and 1 patient with MSS CRC achieved a PR and was treated for 27 months....The greatest reductions in PSA among the prostate cancer patients were achieved in the BID dosing groups with 6/13 patients having PSA reductions of ≥50%."

P1 data • Colorectal Cancer • Prostate Cancer

Combination of Cbl-b inhibitor NX-1607 and CDK4/6 inhibitor abemaciclib enhances anti-tumor immunity through PLCγ1/ERK-mediated T cell activation. (PubMed, Cell Signal) - "These findings suggest that the combination of Cbl-b inhibitors with CDK4/6 inhibitors may have significant synergistic effects in promoting immune cell infiltration and facilitating immune activation. Therefore, this combination represents a promising therapeutic strategy for the treatment of solid tumors."

Journal • Oncology • Solid Tumor • IFNG • IL2

The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. (PubMed, Eur Heart J) - "The study results revealed that KIF13B is a crucial modulator responsible for maintaining proper macrophage efferocytosis to prevent atherosclerotic development through KIF13B/ITCH/CBL/MERTK axis, suggesting that KIF13B will be a potential therapeutic target for the treatment of atherosclerosis in future clinical trials."

Journal • Preclinical • Atherosclerosis • Bone Marrow Transplantation • Cardiovascular • Dyslipidemia • Hematological Malignancies • Hepatology • Lymphoma • Metabolic Disorders • Oncology • Targeted Protein Degradation • Transplantation • MERTK • UBR5

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) - "Upcoming Program Highlights:...NX-1607:...Nurix is evaluating NX-1607 in an ongoing Phase 1 trial in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in the Phase 1a portion. Future clinical updates are anticipated in the second half of 2025."

P1 data • Solid Tumor

Cbl-b inhibitor NX-1607 activates MAPK/ERK signaling pathway and enhances T-cell activation. (PubMed, J Immunother Cancer) - " Taken together, these findings imply that the inhibition of Cbl-b by NX-1607 may enhance the activation of the MAPK/ERK signaling pathway, thereby sustaining T-cell activation. This provides compelling evidence for the molecular mechanism of NX-1607, underscoring the pivotal role of Cbl-b in controlling signal strength in T-cell activation after T-cell receptor (TCR) engagement."

IO biomarker • Journal • B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Targeted Protein Degradation • CD4 • CD69 • CD8 • MAPK3 • PLCG1

Upcoming Program Highlights: NX-1607 (GlobeNewswire) - "Nurix currently is evaluating NX-1607 in an ongoing Phase 1 trial in monotherapy and in a combination cohort utilizing paclitaxel in adults in a range of oncology indications. This study includes a thorough investigation of both dose and schedule in Phase 1a. Future clinical updates are anticipated in 2025."

Trial status • Lymphoma • Solid Tumor

Revisiting the Role of CBL in Liver Fibrosis: Unveiling the Antifibrotic Potential of CBLB inhibitor NX-1607. (PubMed, J Hepatol) - No abstract available

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis

Rational design, optimization, and biological evaluation of novel pyrrolo-pyridone derivatives as potent and orally active Cbl-b inhibitors. (PubMed, Eur J Med Chem) - "Notably, compound B2 stands out, showing superior potency in stimulating IL-2 production in T cells and modulating phosphorylation of key proteins in T-cell receptor signaling. Furthermore, B2 demonstrates favorable pharmacokinetics and significantly inhibits tumor growth in vivo, outperforming NX-1607, which is currently in clinical trials."

Journal • Hematological Malignancies • Lymphoma • Oncology • Targeted Protein Degradation • IL2

Cbl-b inhibition improves manufacturing efficiency and antitumoral efficacy of anti-CD19 CAR-T cells. (PubMed, Int Immunopharmacol) - "In vivo, NX-1607-treated CAR-T cells exhibited superior efficacy against hematological malignancies. These findings highlight Cbl-b as a therapeutic target for enhancing CAR-T cell manufacturing efficiency and antitumor efficacy, underscoring its potential for clinical applications."

Journal • B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases (GlobeNewswire) - "Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia....Drive NX-2127 to proof-of-concept data: Nurix is focusing development on aggressive lymphomas where the combination of BTK degradation and IKZF1/3 degradation have the potential for synergy and significant therapeutic benefit. The company plans to complete dose escalation with new chirally controlled drug product and select recommended Phase 1b dose for selected indications and expects to share additional clinical data after selection of a Phase 1b expansion dose(s) and indication(s). Drive NX-1607 to proof-of-concept data: Nurix is testing both once daily (QD) and twice daily (BID) dosing of NX-1607. With additional patients in the BID dosing arms, Nurix plans to establish a Phase 1b monotherapy dose and expects to share additional clinical data after selection of a Phase 1b expansion dose(s) and indication(s)."

New trial • P1 data • Breast Cancer • Cervical Cancer • Chronic Lymphocytic Leukemia • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Melanoma • Non Small Cell Lung Cancer • Prostate Cancer • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer

NX-1607-101: A Study of NX-1607 in Adults With Advanced Malignancies (clinicaltrials.gov) - P1 | N=345 | Recruiting | Sponsor: Nurix Therapeutics, Inc. | Trial completion date: Feb 2026 ➔ Feb 2028 | Trial primary completion date: Aug 2024 ➔ Aug 2026

Trial completion date • Trial primary completion date • B Cell Lymphoma • Breast Cancer • Castration-Resistant Prostate Cancer • Cervical Cancer • Colorectal Cancer • Diffuse Large B Cell Lymphoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hematological Malignancies • Lung Cancer • Lymphoma • Malignant Pleural Mesothelioma • Melanoma • Mesothelioma • Non Small Cell Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Ovarian Cancer • Pleural Mesothelioma • Prostate Cancer • Richter's Syndrome • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Urothelial Cancer

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) - "NX-5948 is an investigational, orally bioavailable degrader of BTK that is currently being evaluated in the Phase 1b portion of a Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies. By year-end 2024, Nurix plans to present additional clinical data from this study for patients with CLL...Nurix recently introduced a new chirally controlled drug product, which is being evaluated in a dose escalation within this Phase 1a/b trial. Future clinical updates are anticipated in 2025...Nurix is evaluating NX-1607 in an ongoing Phase 1 trial in monotherapy and in a combination cohort utilizing paclitaxel in adults in a range of oncology indications...Nurix anticipates providing a program update by year-end 2024."

P1 data • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Lymphoma • Mantle Cell Lymphoma • Oncology • Solid Tumor

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) - "Upcoming Program Highlights:...NX-2127:...Nurix plans to reinitiate enrollment with the new chirally controlled drug product in a standard dose escalation study within the current Phase 1a/1b trial in the second half of 2024....NX-1607:...In the second half of 2024, Nurix expects to present data from the Phase 1a dose-escalation portion of the trial of NX-1607 and to define dose(s) to enable Phase 1b cohort expansion."

Enrollment status • P1 data • Hematological Malignancies • Solid Tumor

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update (GlobeNewswire) - "NX-1607: In 2024, Nurix expects to present data from the Phase 1a dose-escalation portion of the trial of NX-1607 and to define dose(s) to enable Phase 1b cohort expansion."

P1 data • Hematological Malignancies • Lymphoma • Oncology • Solid Tumor

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting (GlobeNewswire) - "Nurix Therapeutics, Inc...today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA....In 2024, Nurix expects to present data from the Phase 1a dose-escalation portion of the trial of NX-1607 and to define dose(s) to enable Phase 1b cohort expansion."

Commercial • P1 data • Oncology • Solid Tumor

First disclosure of NX-1607, a first-in-class inhibitor of Casitas B-lineage lymphoma b (CBL-B) for immuno-oncology (ACS-Sp 2024) - P1 | "Currently, NX-1607 is undergoing evaluation in a phase I clinical trial across multiple oncology indications (NCT05107674). We present pharmacokinetic-pharmacodynamic (PK-PD) data from this trial."

Immuno-oncology • Hematological Malignancies • Lymphoma • Oncology • Targeted Protein Degradation

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update (GlobeNewswire) - "NX-1607: In 2024, Nurix expects to present data from the Phase 1a dose-escalation portion of the trial of NX-1607 and to define dose(s) to enable Phase 1b cohort expansion."

P1 data • Oncology • Solid Tumor